Drug intelligence / Profile preview

Shengqing Tongqiao Prescription

Development stage: Unknown
Lead developer: Yueyang Hospital of Integrated Traditional Chinese and Western Medicine
Administration: Oral

Overview

Shengqing Tongqiao Prescription is a traditional Chinese medicine prescription currently under investigation for the treatment of mild cognitive impairment in patients with cerebral white matter lesions. It is being evaluated in a randomized, double-blind, double-simulation, parallel-controlled clinical study, indicating an advanced stage of clinical development. In the clinical trial, it is administered as part of an intervention that also includes Western medicine standard treatment and Ginkgo leaf tablets.

Other names: 升清通窍方

Beyond the preview

Go deeper on Shengqing Tongqiao Prescription.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Shengqing Tongqiao Prescription.

Explore the full profile